Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.63 |
| ▸ | MTOR | P42345 | 9/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4936891 | 0.91 | PIK3CA (0.62) | PIK3CAMTORNPSR1MAPTTSHR | |
| SCHEMBL4937645 | 0.88 | PIK3CA (0.61) | PIK3CAMTORNPSR1MAPTTSHR | |
| SCHEMBL4933762 | 0.86 | PIK3CA (0.64) | PIK3CAMTORNPSR1MAPTTSHR | |
| SCHEMBL14271152 | 0.86 | PIK3CA (0.64) | PIK3CAMTORNPSR1MAPTTSHR | |
| SCHEMBL4603731 | 0.86 | PIK3CA (0.64) | PIK3CAMTORNPSR1MAPTTSHR | |
| SCHEMBL4939159 | 0.84 | PIK3CA (0.64) | PIK3CAMTORNPSR1MAPTTSHR | |
| SCHEMBL4937620 | 0.84 | PIK3CA (0.57) | PIK3CAMTORNPSR1MAPTTSHR | |
| SCHEMBL4937750 | 0.84 | PIK3CA (0.59) | PIK3CAMTORNPSR1MAPTTSHR | |
| SCHEMBL4603940 | 0.84 | PIK3CA (0.59) | PIK3CAMTORNPSR1MAPTTSHR | |
| SCHEMBL4941085 | 0.83 | PIK3CA (0.61) | PIK3CAMTORNPSR1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051401-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PASS MARTIN | 2008-02-28 | — | — | US | disclosed |
| CN-101010317-A | 2, 4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer | ASTRAZENECA AB (SE) | 2007-08-01 | — | — | CN | disclosed |
| EP-1778681-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006005918-A1 | 2, 4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051401-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PIK3CA, TYMP, PIK3CB | PIK3CA 1/4885MTOR 288/4885NPSR1 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.